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Abstract. In recent years, abiraterone acetate (AA) and 
enzalutamide (EZL) have become available for the treatment of 
cancer. Prior clinical trials have demonstrated the benefits of 
these agents in males with castration-resistant prostate cancer 
(CRPC). The optimal sequencing of available therapies in the 
context of efficacy and known cross‑resistance remains uncer-
tain. Based on the mechanisms of action and accessible clinical 
data, AA and EZL may be indicated for the early stages of pros-
tate cancer. Until clinical trials are conducted to determine the 
best treatment sequence, individualized therapy is required for 
each patient based on the clinicopathological characteristics. In 
the present study, 46 sequential patients (median age: 77, range 
59-89; median serum PSA level: 56 ng/ml, range 1.5-3,211) with 
CRPC treated with EZL (160 mg/day) were retrospectively 
analyzed between June 2014 and July 2015 at the following 
institutions: Yamagata Prefectural Central Hospital (Yamagata, 
Japan); Yamagata Tokushukai Hospital (Yamagata, Japan); 
Ishinomaki Red Cross Hospital (Ishinomaki, Japan); Kan‑etsu 
Hospital (Tsurugashima, Japan); Niigata Cancer Center 
Hospital (Niigata, Japan); Sakado Central Hospital (Sakado, 
Japan). A total of 18 patients were pre-treated with Docetaxel 
(DOC) and 28 patients were DOC-naïve. Once EZL therapy 
was initiated, increases in prostate specific antigen (PSA) levels 
were observed in 3/18 patients (17%) pre-treated with DOC and 
in 6/20 (30%) who were DOC-naïve. In total, 8/28 DOC-naïve 
patients were treated with AA without EZL. An increase in the 
PSA level was observed in only 1/8 (12%) cases following AA 
treatment in the DOC-naïve group. It was demonstrated that 
AA had a better efficacy in DOC‑naïve patients. The efficacy 
of EZL was limited in AA-pre-treated patients following DOC 
administration.
Introduction
Prostate cancer is the second most commonly diagnosed malig-
nancy in males globally, with an estimated 1,111,700 novel cases 
and 307,500 mortalities per year (1). Metastatic prostate cancer 
is characterized by a period during which the suppression of 
serum testosterone using androgen deprivation therapy is suffi-
cient to control the disease (2). However, this period is followed 
by a transition to castration resistance, during which progres-
sion occurs despite the continued suppression of testosterone. 
This is referred to as metastatic castration-resistant prostate 
cancer (mCRPC) (1). Formerly, this disease state was known 
as hormone-refractory prostate cancer. As it is now understood 
that androgen receptor (AR) signaling remains critical to 
disease progression in castration-resistant disease, this term is 
no longer used (3). The fact that prostate‑specific antigen (PSA) 
rises during mCRPC progression exemplifies this point, as PSA 
is an androgen-regulated gene (1). The clinical relevance of 
targeting androgen signaling in mCRPC is demonstrated by the 
survival advantage conferred by abiraterone acetate (AA) and 
enzalutamide (EZL) in this disease state (1).
Docetaxel (DOC) was the first agent identified to prolong 
patient survival in mCRPC, and it gained regulatory approval 
from the FDA for this indication in 2004 (4). In recent years 
there has been a rapid increase in the number of drugs avail-
able to treat this disease, following the approval of cabazitaxel 
(2010) (5), sipuleucel-T (2010) (6), AA (post-DOC, 2011; 
chemotherapy-naïve, 2012) (7), EZL (post-DOC, 2012; chemo-
therapy-naïve, 2014) (8,9) and radium-223 (2013) (10). In the 
case of AA and EZL, approvals following DOC use were 
initially granted based on the COU-AA-301 and AFFIRM 
trials (9), respectively. Subsequent trials involving patients 
with chemotherapy-naïve mCRPC were conducted for AA 
(COU-AA-302) and EZL (PREVAIL), leading to an extension 
of the approval to the aforementioned population.
The present review focuses on the use of AA in patients 
with chemotherapy-naïve mCRPC. In this retrospective 
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analysis, a variety of treatment sequences were evaluated in 
order to determine the optimal treatment sequence for patients 
with mCRPC.
Patients and methods
A total of 65 patients with CRPC treated with EZL 
(160 mg/day) were retrospectively analyzed at the 
aforementioned institutions between June 2014 and July 
2015. A total of 23 patients were pre-treated with DOC, and 
42 patients were DOC-naïve. Following the initiation of EZL 
treatment, the PSA level was evaluated in 46/65 cases. This 
case series was conducted with those 46 sequential patients 
(median age: 77, range 59-89; median serum PSA level: 
56 ng/ml, range 1.5-3211 ng/ml) with CRPC treated with 
EZL (160 mg/day) at the aforementioned institutions from 
June 2014 to July 2015 (Fig. 1).
Results
Pretreatment with DOC had been administered in 18/46 cases 
(Fig. 2), and the remaining 28 cases were DOC-naïve. EZL 
was administered to the aforementioned 18 patients following 
the pretreatment with DOC; subsequently, a reduction in PSA 
was observed in 15 of these cases. The remaining three cases, 
in which PSA reduction had not been recorded, received AA 
following EZL administration, and a reduction in PSA was 
later revealed in one of the three cases. Of the 28 DOC-naïve 
cases, EZL was prescribed for 20 patients, and a reduction in 
PSA was identified in 14 of these cases. Of the six cases who 
had not exhibited a reduction in PSA levels, and for whom AA 
was prescribed after EZL, only one case then revealed a reduc-
tion in PSA. Of eight cases without pretreatment with DOC for 
which AA was prescribed, seven cases exhibited a reduction 
in PSA levels; in the remaining one case without PSA reduc-
tion, EZL was prescribed following AA administration and a 
reduction in PSA was subsequently identified.
Figure 1. Initial treatment sequences. A total of 65 patients with CRPC 
treated with EZL (160 mg/day) were retrospectively analyzed from June 
2014 to July 2015. A total of 42 patients were DOC-naïve and a further 
23 patients were pre-treated with DOC. Following the initiation of EZL 
treatment, the PSA levels were evaluated in 46/65 cases. EZL, enzalutamide; 
AA, abiraterone acetate; DOC, docetaxel.
Figure 2. Treatment sequences: Within three months of the of treatment initiation, a decline in the PSA levels of ≥30% was observed in 28/46 cases. EZL, 
enzalutamide; AA, abiraterone acetate; DOC, docetaxel; PSA, prostate specific antigen.
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Discussion
During the study, the EZL dose was reduced in three cases due 
to adverse events (body weight loss, fatigue and nausea). In 
the single case of weight loss, the dose was gradually reduced, 
leading to the complete discontinuation of EZL; however, the 
decrease in the PSA level persisted for three months.
AA and EZL are currently available in Japan (11). A prior 
clinical trial has demonstrated the benefits of these agents 
in male patients with CRPC (11). The optimal sequencing 
of therapies in the context of drug efficacy and known 
cross‑resistance remains uncertain. Due to the known mecha-
nisms of action and the available clinical data, AA and EZL 
may be indicated for the treatment of the early stages of 
prostate cancer (11,12). Individualized therapy will remain a 
requirement for each patient based on the clinical and disease 
characteristics until further clinical trials are able to determine 
the optimal treatment sequence.
The efficacy of EZL was limited in AA-pre-treated 
patients following DOC administration. The possibility of 
DOC rechallenge in the treatment of patients with CRPC has 
been limited predominantly by the introduction of AA, EZL 
and cabazitaxel (5). However, it must be considered that the 
reintroduction of DOC may reduce the possibility that one of 
the novel treatment options available could then be admin-
istered. Furthermore, the situation is complicated by recent 
clinical trials that may lead to the early administration of DOC 
in combination with androgen-deprivation therapy, or to novel 
indications of AA and EZL in pre-DOC patients (13,14). In 
this setting, certain prior reports have indicated the possibility 
of the occurrence of cross‑resistance when first‑line chemo-
therapy with DOC was administered after the novel hormonal 
agent AA; by contrast, there have been few instances of 
DOC rechallenge following failure to respond to AA or other 
agents (15,16). The cross-resistance to AA and EZL, as well as 
EWS, has been attributed to the expression of an AR splice 
variant-7 (17,18). In conclusion, further prospective studies are 
required in order to determine the optimal treatment sequence 
in this new anti-androgen era.
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